# NCT05226117 (NCT05226117)

> Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05226117
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: IRCCS San Raffaele
- Conditions: Urothelial Carcinoma
- Interventions: Sacituzumab govitecan
- Enrollment: 44
- Primary outcome: Pathological complete response

## Commentary we found

- X threads: 34
- YouTube: 6
- Podcasts: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct05226117

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05226117", "email": "<work email>"}; the inbox owner confirms by the emailed link.